Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 890 · 1 trial · 1 indication
An adverse event was defined as any untoward medical occurrence in a clinical trial participant. A TEAE was defined as any event with onset after the administration of the first dose of investigational product and up to and including the end of treatment date, or end of trial for participants who discontinued the trial during the treatment period. Clinically significant changes in vital signs, electrocardiograms (ECGs), and safety laboratory analytes were included as TEAEs.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Single Ascending Dose Cohorts |
| AMG 890 | EXPERIMENTAL | Single Ascending Dose Cohorts |
| Name | Type | Description |
|---|---|---|
| AMG 890 | DRUG | Ascending Single Doses of AMG 890 |
| Placebo | DRUG | Calculated volume to match experimental drug. |
Inclusion Criteria: * Men and women with ages between 18 and 70 years old, inclusive. * Protocol-defined elevated plasma Lp(a) level. * Body mass index (BMI) greater than or equal to 18 and less than or equal to 40 kg/m2, at screening. * Women must be of non-reproductive potential. * Other Inclusio...
AMG 890 is an investigational small molecule being developed for cardiovascular disease, specifically for subjects with elevated plasma lipoprotein(a). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AMG 890 is a small molecule designed to address elevated plasma lipoprotein(a), a risk factor for cardiovascular disease. The specific molecular target has not been disclosed in available information.
AMG 890 is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN.
AMG 890 is in Phase 1 clinical development. A Phase 1 study has been completed, and the drug remains investigational, meaning it has not been approved for any use.
AMG 890 has one completed Phase 1 trial, NCT03626662, which evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics in subjects with elevated plasma lipoprotein(a). The trial enrolled 79 participants in the United States and Australia.